Adherence to HAART among patients with HIV: breakthroughs and barriers
- PMID: 12042076
- DOI: 10.1080/09540120220123685
Adherence to HAART among patients with HIV: breakthroughs and barriers
Abstract
Highly active antiretroviral therapy (HAART) has been a major breakthrough for the treatment of patients with HIV; however, adherence to treatment remains a formidable barrier. This paper evaluates the current state-of-the-science in adherence to HAART. Barriers to treatment success, determinants of adherence and interventions to improve adherence are reviewed. Overall, multifaceted interventions appear most promising. We conclude with recommendations to enhance clinical practice and improve treatment outcomes for patients with HIV. Despite substantial attention to adherence in recent years, much more remains to be done to understand and promote adherence to HAART.
Similar articles
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.Antivir Ther. 2004 Jun;9(3):407-14. Antivir Ther. 2004. PMID: 15259903
-
Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women.J Pers Assess. 2007 Dec;89(3):277-90. doi: 10.1080/00223890701629805. J Pers Assess. 2007. PMID: 18001228
-
Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.Cell Mol Biol (Noisy-le-grand). 2003 Dec;49(8):1187-92. Cell Mol Biol (Noisy-le-grand). 2003. PMID: 14983985
-
Challenges of adherence management in human immunodeficiency virus pharmacotherapy.Can J Clin Pharmacol. 2003 Winter;10(4):189-95. Can J Clin Pharmacol. 2003. PMID: 14712324 Review.
Cited by
-
Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.Pharmacoeconomics. 2010;28 Suppl 1:17-34. doi: 10.2165/11587420-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182341 Review.
-
Socioeconomic correlates of dietary diversity and its association with adherence and psychosocial functioning of people living with HIV in rural Zambia.Nutr Health. 2018 Jun;24(2):93-102. doi: 10.1177/0260106018761282. Epub 2018 Mar 7. Nutr Health. 2018. PMID: 29512411 Free PMC article.
-
Asymmetric allylboration of acyl imines catalyzed by chiral diols.J Am Chem Soc. 2007 Dec 12;129(49):15398-404. doi: 10.1021/ja075204v. Epub 2007 Nov 17. J Am Chem Soc. 2007. PMID: 18020334 Free PMC article.
-
Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics.Patient Prefer Adherence. 2012;6:679-84. doi: 10.2147/PPA.S35950. Epub 2012 Sep 25. Patient Prefer Adherence. 2012. PMID: 23055701 Free PMC article.
-
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32. doi: 10.1128/AAC.49.11.4721-4732.2005. Antimicrob Agents Chemother. 2005. PMID: 16251317 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical